ArticleTzu chi medical journal
Utilization of apitherapy in allergic asthma: A systematic review of clinical and preclinical studies.
Article in Tzu chi medical journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This systematic review aimed to summarize the benefit of apitherapy in human and animal models of asthma. Materials and Methods: The procedures in this review were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 protocol, where MEDLINE, ProQuest, and EBSCOhost databases were used to obtain eligible studies dating to 2023. Furthermore, the risk of bias was assessed using Risk of Bias Tool 2.0 (RoB-2) for randomized-control trials and Systematic Review Centre for Laboratory Animal Experimentation's RoB for animal studies. Results: A total of 12 studies were included in the review based on the predetermined eligibility criteria, consisting of 4 human and 8 animal model reports. Among the four human studies, two had a low risk, while the other two had some concerns of bias. In the case of eight animal model of asthma, a total of three domains had a high risk of bias. Moreover, the anti-inflammatory properties of apitherapy were demonstrated by its capacity to inhibit NF-κB, nuclear factor of activated T cells, and IgE antibodies, leading to decreased production of tumor necrosis factor-α, interleukin-2 (IL-2), IL-6, and IL-8, and an increase in IL-10 levels. These beneficial effects were reported to be associated with improvements in clinical manifestations and lung function parameters in human subjects. The use of apitherapy was also related to the restoration of airway structure, and reduction of inflammatory cell infiltration, epithelial thickness, and mucus secretion in lung tissue of animal model of asthma. Conclusion: Based on the results, apitherapy was effective in improving asthma symptoms and reducing inflammation in human and animal models of asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.